EU kicks off review of GSK's linerixibat in PBC. GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.

Gilead and Ipsen make the case for their new therapies for primary biliary cholangitis at EASL congress, as they look ahead to FDA decisions on approval ...